NL-OMON39779
Completed
Not Applicable
TLA Technology: a new DNA diagnostic test to sequence genes that cause the disease and detect new mutations: proof of concept study voor patients with Rendu-Osler-Weber disease. - ROW DNA test
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Rendu-Osler-Weber hereditary hemorrhagic telangiectasia
- Sponsor
- Sint Antonius Ziekenhuis
- Enrollment
- 45
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient with Rendu Osler Weber disease who didn't have a mutation tested in the previous testmethod
- •Patients with known ENG or ALK mutation
Exclusion Criteria
- •Patients without ROW
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
ew approaches in genetic analysis to predict for CRC risk.Bowel CancerCancer - Bowel - AnalCancer - Bowel - Back passage (rectum) or large bowel (colon)Cancer - Bowel - Small bowel (duodenum and ileumACTRN12605000259640CSIRO, Australia300
Completed
Not Applicable
Research on genomic test utilizing next generation sequencer for solid tumors and development of the genome databaseJPRN-UMIN000028388iigata University995
Recruiting
Not Applicable
Implementation of up-front ctDNA analysis into lung cancer care and development of liquid biopsy-based decision support models - the Lungmarker2 studylung cancerlung carcinoma10029107NL-OMON53764Catharina-ziekenhuis800
Recruiting
Not Applicable
Development of non-invasive diagnostic test based on fetal DNA isolated from maternal blood (NATERA-study)chromosomal aberriationsgenetic defect10083624NL-OMON37477eids Universitair Medisch Centrum300
Completed
Not Applicable
Next Generation pErsonalized tX(Therapy) With Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial)Metastatic Gastrointestinal CancerGenitourinary CancerNCT02140463Samsung Medical Center229